The Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma) drugs in development market research report provides comprehensive information on the therapeutics under development for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma). Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma) and features dormant and discontinued products.

GlobalData tracks 47 drugs in development for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma) by 42 companies/universities/institutes. The top development phase for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma) is phase ii with 27 drugs in that stage. The Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma) pipeline has 41 drugs in development by companies and six by universities/ institutes. Some of the companies in the Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma) pipeline products market are: AbbVie, General Hospital of the People’s Liberation Army and BeiGene.

The key targets in the Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma) pipeline products market include Cells Expressing B Lymphocyte Antigen CD19 (B Lymphocyte Surface Antigen B4 or Differentiation Antigen CD19 or T Cell Surface Antigen Leu 12 or CD19), Cells Expressing B Lymphocyte Antigen CD20 (B Lymphocyte Surface Antigen B1 or Bp35 or Leukocyte Surface Antigen Leu 16 or Membrane Spanning 4 Domains Subfamily A Member 1 or CD20 or MS4A1), and B Lymphocyte Antigen CD19 (B Lymphocyte Surface Antigen B4 or Differentiation Antigen CD19 or T Cell Surface Antigen Leu 12 or CD19).

The key mechanisms of action in the Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma) pipeline product include Cytotoxic To Cells Expressing B Lymphocyte Antigen CD19 (B Lymphocyte Surface Antigen B4 or Differentiation Antigen CD19 or T Cell Surface Antigen Leu 12 or CD19) with 13 drugs in Pre-Registration. The Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma) pipeline products include nine routes of administration with the top ROA being Intravenous and five key molecule types in the Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma) pipeline products market including Small Molecule, and Monoclonal Antibody.

Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma) overview

Extranodal marginal zone B-cell lymphoma (EMZL), also known as mucosa-associated lymphoid tissue (MALT) lymphoma, is a rare type of non-Hodgkin lymphoma that originates in the marginal zone B cells outside of the lymph nodes. It often develops in various extranodal sites of the body, particularly mucosal tissues such as the stomach, salivary glands, lungs, thyroid, and other organs. MALT lymphoma represents a small percentage of non-Hodgkin lymphomas. It is most diagnosed in adults, with a median age at diagnosis typically in the 60s, although it can occur at any age. MALT lymphoma often arises due to chronic inflammation or immune responses in specific tissues, leading to the proliferation of marginal zone B cells. In many cases, it is associated with chronic infections or autoimmune disorders that trigger persistent antigen stimulation, such as Helicobacter pylori infection in gastric MALT lymphoma or Sjögren’s syndrome in salivary gland MALT lymphoma.

For a complete picture of Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma)’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.